LAM-561 is under clinical development by Laminar Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LAM-561’s likelihood of approval (LoA) and phase transition for Malignant Glioma took place on 26 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 26 May 2022 increased LAM-561’s Phase Transition Success Rate (PTSR) for Solid Tumor.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LAM-561 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LAM-561 overview

LP-561A1 (Minerval, 2-OHOA) is under development for the treatment of solid tumors including malignant glioma and glioblastoma. It is administered orally. Minerval is an oleic acid synthetic analogue. The drug candidate is based on membrane lipid therapy (MLP) technology and targets sphingomyelin synthase. It was also under development for the treatment of pancreatic cancer, prostate cancer, leukemias, non-small cell lung cancer, colorectal cancer and breast cancer.

Laminar Pharmaceuticals overview

Laminar Pharmaceuticals (Laminar Pharmaceutical) is a biopharmaceutical company that designs and develops new generations of medicines. It focused on rare, pediatric, and geriatric diseases, especially those with unmet medical needs and also developing melitherapy drugs for Alzheimer’s disease, and for metabolic, cardiovascular and inflammatory diseases. The company’s product pipeline includes LAM561 in cancer, LAM226 in Alzheimer’s disease, LAM204 in inflammation, and LAM30171 is the latest candidate, a new fatty acid derivative currently being investigated as a potential treatment for cancer and metabolic disorders. Laminar Pharmaceutical is headquartered in Palma, Spain.

Quick View LAM-561 LOA Data

Report Segments
  • Innovator
Drug Name
  • LAM-561
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.